SCHEDULE: Intracoastal Capital Reports 0.4% Stake in Enveric Biosciences

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 0.4% beneficial ownership stake in Enveric Biosciences, Inc. as of September 24, 2025.

Summary

• Reporting Persons: Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
• Issuer: Enveric Biosciences, Inc. (Common Stock, par value $0.01 per share, CUSIP 29405E406).
• As of September 24, 2025, the Reporting Persons beneficially own 19,333 shares of Enveric Biosciences Common Stock.
• This current beneficial ownership represents approximately 0.4% of the company's outstanding Common Stock, based on 5,079,612 shares outstanding plus 19,333 shares issued upon warrant exercise.
• The 19,333 shares were acquired through the exercise of Intracoastal Warrant 3.
• Immediately following a transaction on September 17, 2025, the Reporting Persons were deemed to have beneficial ownership of 266,668 shares, representing approximately 5.2% of the Common Stock.
• Two additional warrants, Intracoastal Warrant 1 and Intracoastal Warrant 2, each for 266,668 shares, remain unexercised due to conditions requiring stockholder approval and 4.99% beneficial ownership blocker provisions.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a routine disclosure of beneficial ownership and generally neutral in sentiment. The passive nature of the investment (not for control) and the relatively small current stake (0.4%) do not indicate strong positive or negative implications for the company's immediate prospects, though the potential for future warrant exercise represents a future capital event.

Positives

• The reporting persons are not seeking to influence or change control of the issuer, indicating a passive investment stance that may reduce concerns about activist intervention.

Negatives

• The beneficial ownership reported by the Reporting Persons has decreased from approximately 5.2% (266,668 shares) immediately following a transaction on September 17, 2025, to 0.4% (19,333 shares) as of September 24, 2025. This reduction in reported stake could be interpreted as a decrease in the Reporting Persons' immediate active investment or influence.

Risks

• The exercisability of Intracoastal Warrant 1 and Intracoastal Warrant 2, each for 266,668 shares, is contingent upon future stockholder approval, introducing uncertainty regarding the full realization of the potential investment.
• Blocker provisions in all warrants prevent the holder from exceeding 4.99% beneficial ownership, limiting the immediate ability to significantly increase their stake without further corporate actions or waivers.

Future Outlook

The full exercisability of Intracoastal Warrant 1 and Intracoastal Warrant 2, each for 266,668 shares, is dependent on future stockholder approval, which will determine the extent of the Reporting Persons' potential increased stake in Enveric Biosciences.

Industry Context

This filing is a standard disclosure of beneficial ownership by an investor group, common in the biotech or pharmaceutical industry for companies like Enveric Biosciences, which often rely on external investment. The presence of blocker provisions in warrants is a common mechanism to manage ownership thresholds and avoid triggering certain regulatory or corporate governance requirements.

Comparison to Industry Standards

• The filing is a standard beneficial ownership report and does not contain operational or financial performance data that would allow for a direct comparison to industry benchmarks or specific comparable companies, projects, and results.
• The reported 0.4% stake is a relatively small passive investment, typical for non-activist investors in publicly traded companies.
• The use of warrants with blocker provisions is a common financial instrument for investors to acquire a stake while managing regulatory thresholds (e.g., 5% beneficial ownership reporting requirements) and avoiding control-related implications.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant investor's stake and intentions. The potential future exercise of warrants could lead to dilution if not managed carefully, but also represents a source of capital.
• Management: Awareness of a passive investor group holding warrants, whose full exercise is contingent on stockholder approval.

Next Steps

• Stockholder approval for the issuance of shares upon exercise of Intracoastal Warrant 1 and Intracoastal Warrant 2.
• Potential future exercise of Intracoastal Warrant 1 and Intracoastal Warrant 2 by Intracoastal Capital LLC.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of beneficial ownership by Intracoastal Capital LLC and its principals. The reported 0.4% stake is relatively small and explicitly stated as not being for the purpose of influencing control, suggesting a passive investment. While there are unexercised warrants that could increase their stake, their exercisability is contingent on future stockholder approval and subject to blocker provisions. The filing does not contain new operational or financial performance data that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as there's no immediate catalyst for a strong buy or sell decision based solely on this ownership update.

Keywords

Enveric Biosciences, Intracoastal Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment, Shareholder Stake